Acurx Pharmaceuticals (ACXP) Assets Average (2021 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Assets Average came in at $8.6 million in Q1 2026, up 98.88% YoY from $4.3 million in Q1 2025, and up 24.9% on a QoQ basis from $6.9 million in Q4 2025.
Acurx Pharmaceuticals (ACXP) Assets Average (2021 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 6 years of Assets Average data on file, last reported at $8.6 million in Q1 2026.
- Quarterly Assets Average rose 98.88% year-over-year to $8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (up 98.88% YoY) and the FY2025 annual result came in at $5.8 million, changed 0.17% from the prior year.
- Assets Average rose to $8.6 million in Q1 2026, from $6.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $12.3 million in Q1 2022 to a low of $4.3 million in Q1 2025.
- A 5-year average of $7.9 million and a median of $8.2 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2025 — Assets Average plunged 48.49% — and 2026, when it jumped 98.88%.
- Tracing ACXP's Assets Average over 5 years: stood at $10.2 million in 2022, then dropped by 26.84% to $7.4 million in 2023, then sank by 33.81% to $4.9 million in 2024, then surged by 40.18% to $6.9 million in 2025, then increased by 24.9% to $8.6 million in 2026.
- The last three Assets Average figures came in at $8.6 million (Q1 2026), $6.9 million (Q4 2025), and $6.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Acurx Pharmaceuticals | 6.38 Mn | 6.38 Mn | - | 10.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.26 Mn |
| Mar 31, 2026 | 8.61 Mn |
| Dec 31, 2025 | 6.90 Mn |
| Sep 30, 2025 | 6.13 Mn |
| Jun 30, 2025 | 5.48 Mn |
| Mar 31, 2025 | 4.33 Mn |
| Dec 31, 2024 | 4.92 Mn |
| Sep 30, 2024 | 6.28 Mn |
| Jun 30, 2024 | 7.84 Mn |
| Mar 31, 2024 | 8.41 Mn |
| Dec 31, 2023 | 7.43 Mn |
| Sep 30, 2023 | 8.20 Mn |
| Jun 30, 2023 | 8.31 Mn |
| Mar 31, 2023 | 8.38 Mn |
| Dec 31, 2022 | 10.16 Mn |
| Sep 30, 2022 | 10.10 Mn |
| Jun 30, 2022 | 10.29 Mn |
| Mar 31, 2022 | 12.29 Mn |
| Dec 31, 2021 | 14.12 Mn |
| Sep 30, 2021 | 16.21 Mn |